South African venture studio OneBio has secured a ZAR 20 million (USD 1.16 million) grant to advance its mission of commercializing biotechnology research across Africa. This significant capital injection is set to accelerate the firm's unique venture-building program, which focuses on transforming laboratory science into market-ready enterprises. The funding underscores a growing investor confidence in the continent's burgeoning deep tech sector, signaling a pivotal moment for science-driven innovation.
A Hybrid Model for High-Risk Innovation
Led by co-founders Michael Fichardt, Nick Walker, and Gian-Marco Melfi, OneBio employs a hybrid model that merges venture capital investment with hands-on startup creation. Unlike traditional investors, the studio actively builds biotech companies from the ground up, a strategy that provides greater operational control. This intensive approach is designed to de-risk early-stage ventures in a sector known for its complexity and long development timelines.
Operating a biotech studio in Africa presents formidable challenges, including limited access to advanced wet lab infrastructure and fragmented regulatory landscapes. The path from research to commercialization is often protracted, requiring substantial capital and specialized expertise to navigate. OneBio's model directly confronts these hurdles by providing a structured and supportive ecosystem for its portfolio companies to grow.
Navigating the Realities of Deep Tech
Since its inception in 2018, OneBio's portfolio reflects the high-stakes nature of its work, having backed 16 ventures. The firm has recorded eight exits, but also six shutdowns, a reality that highlights the inherent difficulties of building science-heavy startups in capital-constrained markets. This track record offers a transparent look at both the potential and the pitfalls of pioneering deep tech on the continent.
Despite the high attrition rate, several portfolio companies demonstrate clear technical competence and commercial promise. Notable successes include LifeQ, a revenue-generating wearable health company that has raised over $47 million, and CapeBio, a biotech firm that capitalized on pandemic-era testing demands. These ventures validate the studio's ability to build scientifically sound and commercially relevant businesses from African research.
The firm continues to cultivate a strong pipeline of new ventures, recently co-leading a ZAR 29 million pre-seed round for Altera Biosciences, a startup focused on transplant medicine. Other active companies such as Biomine and Immobazyme are exploring innovations in microbiome health and precision fermentation. This ongoing activity signals a robust commitment to fostering the next generation of African biotech breakthroughs.
The Broader African Venture Studio Landscape
OneBio's progress occurs as the venture studio model gains significant traction across Africa as a method for bypassing local market inefficiencies. Studios are increasingly engineering startups internally to provide them with a stronger foundation for success. This trend indicates a strategic evolution in how early-stage companies are conceptualized and built on the continent.
Entities like Nigeria's Delta40 and Kenya's Purple Elephant Ventures are also making substantial impacts in their respective markets. These studios are attracting significant capital and developing robust portfolios in diverse sectors from fintech to tourism technology. Their collective emergence is fostering a more dynamic and supportive ecosystem for innovation across Africa.
The new grant provides OneBio with critical runway to scale its operations and expand its blueprint into key markets like Nigeria, Kenya, and Egypt. While the studio has proven its capacity to translate complex research into functional scientific businesses, its ultimate test lies ahead. The focus now shifts to proving that these heavily engineered companies can scale successfully and deliver the lucrative exits that investors demand.